|Safety, activity, and immune correlates of anti–PD-1 antibody in cancer|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
|Safety and activity of anti–PD-L1 antibody in patients with advanced cancer|
JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ...
New England Journal of Medicine 366 (26), 2455-2465, 2012
|Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates|
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167, 2010
|Immune checkpoint blockade: a common denominator approach to cancer therapy|
SL Topalian, CG Drake, DM Pardoll
Cancer cell 27 (4), 450-461, 2015
|Inflammation in prostate carcinogenesis|
AM De Marzo, EA Platz, S Sutcliffe, J Xu, H Grönberg, CG Drake, Y Nakai, ...
Nature Reviews Cancer 7 (4), 256-269, 2007
|A draft map of the human proteome|
MS Kim, SM Pinto, D Getnet, RS Nirujogi, SS Manda, R Chaerkady, ...
Nature 509 (7502), 575-581, 2014
|Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity|
SL Topalian, CG Drake, DM Pardoll
Current opinion in immunology 24 (2), 207-212, 2012
|Role of LAG-3 in regulatory T cells|
CT Huang, CJ Workman, D Flies, X Pan, AL Marson, G Zhou, EL Hipkiss, ...
Immunity 21 (4), 503-513, 2004
|Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …|
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
|Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape|
SR Woo, ME Turnis, MV Goldberg, J Bankoti, M Selby, CJ Nirschl, ...
Cancer research 72 (4), 917-927, 2012
|Mechanisms of immune evasion by tumors|
CG Drake, E Jaffee, DM Pardoll
Advances in immunology 90, 51-81, 2006
|Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas|
J Zeng, AP See, J Phallen, CM Jackson, Z Belcaid, J Ruzevick, N Durham, ...
International Journal of Radiation Oncology* Biology* Physics 86 (2), 343-349, 2013
|Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity|
TJ Harris, JF Grosso, HR Yen, H Xin, M Kortylewski, E Albesiano, ...
The Journal of Immunology 179 (7), 4313-4317, 2007
|Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma|
S Lyford-Pike, S Peng, GD Young, JM Taube, WH Westra, B Akpeng, ...
Cancer research 73 (6), 1733-1741, 2013
|Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody|
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
|Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment|
M Kortylewski, H Xin, M Kujawski, H Lee, Y Liu, T Harris, C Drake, ...
Cancer cell 15 (2), 114-123, 2009
|A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells|
PE Zarek, CT Huang, ER Lutz, J Kowalski, MR Horton, J Linden, ...
Blood 111 (1), 251-259, 2008
|Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing|
KS Sfanos, TC Bruno, CH Maris, L Xu, CJ Thoburn, AM DeMarzo, ...
Clinical Cancer Research 14 (11), 3254-3261, 2008
|LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems|
JF Grosso, CC Kelleher, TJ Harris, CH Maris, EL Hipkiss, A De Marzo, ...
The Journal of clinical investigation 117 (11), 3383-3392, 2007
|Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer|
CG Drake, EJ Lipson, JR Brahmer
Nature reviews Clinical oncology 11 (1), 24, 2014